INTERLEUKIN 28B GENE POLYMORPHISMS AS A PREDICTOR OF TREATMENT RESPONSE IN EGYPTIANS WITH CHRONIC HEPATITIS C.

Interleukin 28B Polymorphism as a Predictor of Response to Treatment of Egyptian HCV Patients Working in Nuclear Material Authority

Impact of gene polymorphism on Egyptian HCV patients under direct antiviral Drugs

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclat

Impact of IL28B Polymorphism on the Response to Treatment of Hepatitis C with Interferon Based Therapy or Direct Acting Antivirals

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients

Evaluation of Sofosbuvir plus Ribavirinin Treatment of Cirrhotic Hepatitis C Patients: An Egyptian Study

Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon in Management of Egyptian Chronic Hepatitis C Patients

Efficacy of Sofosbuvir plus Daclatasvir in Treatment of Chronic HCV Infection in Egyptian Patients: A Prospective Cohort Study

Comparative study between the efficacy of using sofosbuvir/daclatasvir and sofosbuvir/ledipasvir in treatment of hepatitis C virus in Egypt